PASTORCZAK, Agata, Bartosz SZMYD, Marcin BRAUN, Joanna MADZIO, Kamila WYPYSZCZAK, Pawel SZTROMWASSER, Wojciech FENDLER, Marzena WOJTASZEWSKA, Jedrzej CHRZANOWSKI, Wieslawa GRAJKOWSKA, Hanna GREGOREK, Anna WAKULINSKA, Bernarda KAZANOWSKA, Zdenka KŘENOVÁ, Dilys D WEIJERS, Roland P KUIPER and Wojciech MLYNARSKI. Clinical and laboratory diversity of diffuse large B-cell lymphomas in children with Nijmegen breakage syndrome. Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2023, vol. 108, No 10, p. 2808-2813. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2022.282325.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Clinical and laboratory diversity of diffuse large B-cell lymphomas in children with Nijmegen breakage syndrome
Authors PASTORCZAK, Agata (guarantor), Bartosz SZMYD, Marcin BRAUN, Joanna MADZIO, Kamila WYPYSZCZAK, Pawel SZTROMWASSER, Wojciech FENDLER, Marzena WOJTASZEWSKA, Jedrzej CHRZANOWSKI, Wieslawa GRAJKOWSKA, Hanna GREGOREK, Anna WAKULINSKA, Bernarda KAZANOWSKA, Zdenka KŘENOVÁ (203 Czech Republic, belonging to the institution), Dilys D WEIJERS, Roland P KUIPER and Wojciech MLYNARSKI.
Edition Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2023, 0390-6078.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 10.100 in 2022
RIV identification code RIV/00216224:14110/23:00133398
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3324/haematol.2022.282325
UT WoS 001109389400020
Keywords in English large B-cell lymphomas; children
Tags 14110321, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 14/2/2024 09:43.
Abstract
Nijmegen breakage syndrome (NBS) is an inherited DNA repair disorder characterized by a high predisposition to develop lymphoid malignancies during childhood, with diffuse large B-cell lymphoma (DLBCL) being one of the leading types. Due to concomitant immunodeficiency and an increased risk of chemotherapy-induced toxicity, NBS patients often require modified and individualized cancer treatment. Nevertheless, they rarely achieve progressionand relapse-free long-term survival rates without hematopoietic stem cell transplantation. Unfavorable outcome of lymphomas in NBS may result not only from the reduction of drug dosages but could be associated with molecular aberrations occurring on the background of chromosomal instability. Therefore, we aimed to investigate clinical outcome, histopathological features, and genomic alterations of DLBCL in pediatric patients with NBS.
Links
MUNI/A/1395/2022, interní kód MUName: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“
Investor: Masaryk University
PrintDisplayed: 19/7/2024 15:18